Top Markets
Coin of the day
Fennec Pharmaceuticals Inc. Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

FENC
株式のランク #14209
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading... Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
株価
$12.33
最終同期: 2026-08-31
時価総額
$428.31M
変化(1日)
0.49%
変化(1年)
39.01%
US
取引 Fennec Pharmaceuticals Inc. (FENC)

カテゴリー

Fennec Pharmaceuticals Inc.(FENC)の配当利回りの履歴
Fennec Pharmaceuticals Inc.(銘柄コード: FENC)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Fennec Pharmaceuticals Inc.(FENC)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)